Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc. announced that the US FDA has cleared Northwestern University’s Investigational New Drug (IND) application for Calidi’s CLD-101, a novel stem-cell based platform designed to deliver oncolytic viruses to tumors, enhancing their antitumor effects.